Table 1.

Patient characteristics and outcome.

No	Age/sex	Tumor/stage	Induction chemotherapy	Indication for bladder preservation	Concurrent chemotherapy	Pelvic RT/Gy	Bladder RT/Gy	Initial evaluation	Local recurrence	Distant recurrence	Status	F/U in months
1	53/M	T3bN0	Gemcitabine Cisplatin	Recommended by physician	Cisplatin	45	–	CR	No	No	Alive NED	27
2	63/M	T2N0	Gemcitabine Carboplatin	Patient preference	Cisplatin	45	–	CR	No	No	Alive NED	47
3	74/M	T2aN0	Gemcitabine Carboplatin	Patient preference	Cisplatin	45	19	CR	No	No	Alive NED	11
4	71/M	T2N0	Gemcitabine Cisplatin	Recommended by physician	Carboplatin	45	19	CR	No	No	Alive NED	6
5	61/M	T2N0	Gemcitabine Cisplatin	Cardiac disease	Cisplatin	45	19	CR	No	No	Alive NED	21
6	61/M	T2aN0	Gemcitabine Carboplatin	Recommended by physician	Carboplatin	45	–	CR	No	No	Dead NED	14
7	65/M	T2N0	Gemcitabine Cisplatin	Recommended by physician	Cisplatin	45	–	CR	No	Lung Bone	Dead DTD	48
8	61/F	T2N0	Gemcitabine Cisplatin	Morbid obesity	Cisplatin	45	16	CR	No	Pelvic LNs	Dead DTD	47
9	60/M	T3N0	Gemcitabine Cisplatin	Recommended by physician	Cisplatin	45	–	Not evaluated	–	–	Alive UDS	3
10	56/F	T3bN0	Gemcitabine Cisplatin	Recommended by physician	Cisplatin	45	–	PR	Residual disease	Pelvic LNs	Dead DTD	16
11	63/M	T2N0	Gemcitabine Cisplatin*	Patient preference	Cisplatin	45	–	PR	Residual disease	Bone	Dead DTD	4
12	49/M	T2N0	Gemcitabine Cisplatin	Recommended by physician	Carboplatin	45	–	PR	Residual disease	PALNs Bone	Alive WD	24
13	41/F	T2N0	Gemcitabine Carboplatin	Recommended by physician	Cisplatin	45	–	Not evaluated	–	Liver Lung Bone	Dead DTD	5
14	59/M	T2aN0	Gemcitabine Cisplatin	COPD	Cisplatin	45	–	Not evaluated	–	Lung	Dead DTD	14

PALN, para-aortic lymph node; NED, no evidence of disease; DTD, due to disease; UDS, unknown disease status; WD, with disease; COPD, chronic obstructive pulmonary disease.

^*Patient could not tolerate regimen (developed meningitis).